Literature DB >> 26998024

Aggressive muscle-invasive bladder cancer with sarcomatoid differentiation in a 10-year-old girl: A case report.

Zijian Wang1, Wei Xiong1, Cizhong Pan1, Liang Zhu1, Xinjun Wang1, Zhichao Huang1, Xiaokun Zhao1, Zhaohui Zhong1.   

Abstract

The present study reports an unusual case of high-grade bladder cancer in a 10-year-old girl who complained of painless hematuria and urinary frequency. The tumor displayed sarcomatoid differentiation and an aggressive behavior, which required the administration of adjuvant chemotherapy. However, the disease progressed and the patient succumbed 6 months after surgery. It is known that the majority of malignant bladder cancers in pediatric patients are low-grade and present at an early stage, whereas sarcomatoid differentiation in the setting of a high-grade urothelial carcinoma is indicative of a poor prognosis. It is important that gross hematuria in pediatric patients is investigated carefully. It is recommended that the management of urothelial neoplasia in young patients should be predominantly decided on the basis of the grade and stage of the tumor rather than the age of the patient.

Entities:  

Keywords:  adjuvant therapy; bladder cancer; children; radical cystectomy

Year:  2016        PMID: 26998024      PMCID: PMC4774393          DOI: 10.3892/etm.2016.3012

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  19 in total

1.  Urothelial neoplasms in patients 20 years or younger: a clinicopathological analysis using the world health organization 2004 bladder consensus classification.

Authors:  Samson W Fine; Peter A Humphrey; Louis P Dehner; Mahul B Amin; Jonathan I Epstein
Journal:  J Urol       Date:  2005-11       Impact factor: 7.450

2.  Carcinosarcoma of the urinary bladder.

Authors:  G Gedikoğlu; C Sökmensüer; F Söylemezoğlu; C Koçal
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 3.  Unique clinicopathologic and molecular characteristics of urinary bladder tumors in children and young adults.

Authors:  Sean R Williamson; Antonio Lopez-Beltran; Gregory T MacLennan; Rodolfo Montironi; Liang Cheng
Journal:  Urol Oncol       Date:  2010-09-29       Impact factor: 3.498

Review 4.  Transitional cell carcinoma of the bladder in children.

Authors:  A Serrano-Durbá; C Domínguez-Hinarejos; C Reig-Ruiz; M Fernández-Córdoba; F García-Ibarra
Journal:  Scand J Urol Nephrol       Date:  1999-02

Review 5.  Management of superficial and muscle-invasive urothelial cancers of the bladder.

Authors:  Matthew J Resnick; Jeffrey C Bassett; Peter E Clark
Journal:  Curr Opin Oncol       Date:  2013-05       Impact factor: 3.645

6.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Authors:  Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

7.  Transitional cell carcinoma of the bladder in young adults: presentation, natural history and outcome.

Authors:  Ofer Yossepowitch; Guido Dalbagni
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

8.  [Urothelial tumor of the bladder in children].

Authors:  F Poddevin; M Bayart
Journal:  J Urol (Paris)       Date:  1995

9.  Transitional cell papilloma of the bladder in a child: a case report and review of literature.

Authors:  Gordon Thomas; Parshotam Gera; Susan Arbuckle; Ralph Cohen
Journal:  J Pediatr Urol       Date:  2005-08-02       Impact factor: 1.830

10.  The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial.

Authors:  D G Skinner; J R Daniels; C A Russell; G Lieskovsky; S D Boyd; P Nichols; W Kern; J Sakamoto; M Krailo; S Groshen
Journal:  J Urol       Date:  1991-03       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.